GOSS vs. CYRX, ALT, PHAR, CMPS, KALV, APLT, ATXS, CRBP, MREO, and IGMS
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Cryoport (CYRX), Altimmune (ALT), Pharming Group (PHAR), COMPASS Pathways (CMPS), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Astria Therapeutics (ATXS), Corbus Pharmaceuticals (CRBP), Mereo BioPharma Group (MREO), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.
Cryoport (NASDAQ:CYRX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap transportation companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
Gossamer Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -50.17%. Gossamer Bio's return on equity of -15.19% beat Cryoport's return on equity.
Cryoport received 93 more outperform votes than Gossamer Bio when rated by MarketBeat users. However, 65.32% of users gave Gossamer Bio an outperform vote while only 65.21% of users gave Cryoport an outperform vote.
Cryoport has higher revenue and earnings than Gossamer Bio. Cryoport is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cryoport had 4 more articles in the media than Gossamer Bio. MarketBeat recorded 5 mentions for Cryoport and 1 mentions for Gossamer Bio. Cryoport's average media sentiment score of 1.77 beat Gossamer Bio's score of 0.24 indicating that Gossamer Bio is being referred to more favorably in the news media.
Cryoport currently has a consensus target price of $18.25, suggesting a potential upside of 58.56%. Gossamer Bio has a consensus target price of $7.65, suggesting a potential upside of 1,367.77%. Given Cryoport's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Cryoport.
92.9% of Cryoport shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 10.1% of Cryoport shares are held by insiders. Comparatively, 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Cryoport has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.
Summary
Gossamer Bio beats Cryoport on 9 of the 17 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
